Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Liabilities and Shareholders Equity: 2021-2024

Historic Liabilities and Shareholders Equity for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to $193.6 million.

  • Amylyx Pharmaceuticals' Liabilities and Shareholders Equity rose 44.68% to $362.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $970.6 million, marking a year-over-year decrease of 36.05%. This contributed to the annual value of $193.6 million for FY2024, which is 62.58% down from last year.
  • As of FY2024, Amylyx Pharmaceuticals' Liabilities and Shareholders Equity stood at $193.6 million, which was down 62.58% from $517.5 million recorded in FY2023.
  • Over the past 5 years, Amylyx Pharmaceuticals' Liabilities and Shareholders Equity peaked at $517.5 million during FY2023, and registered a low of $105.6 million during FY2021.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $391.5 million (2022), whereas its average is $367.5 million.
  • As far as peak fluctuations go, Amylyx Pharmaceuticals' Liabilities and Shareholders Equity surged by 270.64% in 2022, and later slumped by 62.58% in 2024.
  • Yearly analysis of 4 years shows Amylyx Pharmaceuticals' Liabilities and Shareholders Equity stood at $105.6 million in 2021, then spiked by 270.64% to $391.5 million in 2022, then spiked by 32.19% to $517.5 million in 2023, then plummeted by 62.58% to $193.6 million in 2024.